Transcutaneous Monitors Market Size and Share
Transcutaneous Monitors Market Analysis by Mordor Intelligence
The transcutaneous monitors market was valued at USD 278.39 million in 2025 and is forecast to advance to USD 378.74 million by 2030, reflecting a steady 6.35% CAGR. The expansion is driven by rapid device miniaturization, clinical confidence in non-invasive blood-gas substitutes, and the growing expectation that monitoring hardware will link seamlessly with analytics platforms. Hospitals remain the principal buyers, yet demand is spreading to specialty clinics and home-care programs as reimbursement widens and as clinicians seek workflow-friendly equipment. Advancements in luminescence sensors, photoacoustic spectroscopy, and AI algorithms are shortening product cycles while improving accuracy, which in turn encourages replacement purchases [1]U.S. Food and Drug Administration, “Medical Device Databases,” fda.gov . Meanwhile, combined-parameter platforms are taking share from single-parameter devices because multidisciplinary teams prefer consolidated views of oxygen, carbon dioxide, and other biomarkers.
Key Report Takeaways
- By application, Blood Gas Monitoring led with 41.44% of the transcutaneous monitors market share in 2024, while Wound Healing is poised to grow at a 7.12% CAGR through 2030.
- By end user, Hospitals commanded 67.78% share of the transcutaneous monitors market size in 2024; Specialty Clinics are projected to expand at a 7.19% CAGR to 2030.
- By parameter monitored, transcutaneous CO₂ sensors accounted for 44.41% of the transcutaneous monitors market size in 2024, whereas Combined Parameters systems are set to progress at a 7.03% CAGR over the same period.
- By patient age group, Adults comprised 45.89% of total 2024 revenue, yet the Neonatal segment shows the fastest advance at 7.21% CAGR through 2030.
- By geography, North America comprised 40.12% of total 2024 revenue, yet the Asia-Pacific segment shows the fastest advance at 7.23% CAGR through 2030.
Global Transcutaneous Monitors Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Growing prevalence of respiratory diseases | +1.8% | Global, concentrated in North America & Europe | Medium term (2-4 years) |
Technological miniaturization & sensor accuracy gains | +1.5% | Global, led by Asia-Pacific innovation hubs | Long term (≥ 4 years) |
Rise in chronic disorders necessitating continuous monitoring | +1.2% | Global, especially developed markets | Long term (≥ 4 years) |
Demand spike for non-invasive neonatal & critical-care monitoring | +1.0% | North America & EU, expanding to APAC | Medium term (2-4 years) |
AI-enabled wearable capnometry for home & sleep diagnostics | +0.7% | North America & EU early adoption | Long term (≥ 4 years) |
Hyperbaric-medicine expansion driving TcPO₂ adoption | +0.5% | North America & Europe; selective APAC | Medium term (2-4 years) |
Source: Mordor Intelligence
Growing Prevalence of Respiratory Diseases
Chronic obstructive pulmonary disease, sleep apnea, and post-viral respiratory complications are driving sustained demand for continuous non-invasive monitoring [2]Radiometer America, “Clinical Performance of Transcutaneous Monitoring in Neonates,” radiometeramerica.com . Hospitals that introduced transcutaneous CO₂ sensors in neonatal intensive care units reduced arterial blood draws by 25%, lowering infection risk and nursing time. Home-based sleep-diagnostic programs using smartwatch-linked oximetry algorithms achieved 89.4% sensitivity, illustrating the shift from clinic-centric testing to consumer-friendly screening [3]Radiometer America, “Clinical Performance of Transcutaneous Monitoring in Neonates,” radiometeramerica.com . U.S. coverage determinations now deem transcutaneous systems medically necessary for restrictive thoracic disorders, broadening reimbursement and reinforcing their role in value-based care. Together, disease burden and policy alignment underpin a robust outlook for the transcutaneous monitors market.
Technological Miniaturization & Sensor Accuracy Gains
Luminescence, photoacoustic, and electronic-paramagnetic-resonance sensing have trimmed probe footprints while dispensing with heating membranes, clearing a path for round-the-clock wearables that rival arterial sampling accuracy. Non-contact epidermal flux monitors showcased by Nature reported clinically acceptable variance without direct skin coupling, extending use cases to fragile or burn patients. Masimo embedded ML-driven “Sleep Halo” analytics in consumer devices that log 70,000 daily health points, illustrating how software stickiness can lengthen hardware life cycles. The U.S. Food & Drug Administration recently cleared laser-based oximeters that correct melanin-related signal drop, signaling regulatory support for equity-minded accuracy upgrades. Such breakthroughs are expected to influence platform specifications for at least the next product generation.
Rise in Chronic Disorders Necessitating Continuous Monitoring
Health-systems are migrating from episodic to longitudinal care models, and payers are rewarding devices that enable early intervention. Insertable cardiac monitors saved USD 4,532 per patient relative to legacy testing while generating 0.30 additional QALYs, demonstrating economic justification for continuous monitoring. Abbott’s alliance with Medtronic on closed-loop glucose control highlights how transcutaneous sensing is embedding itself in therapeutic automation pathways. Roche obtained CE Mark for a hypoglycemia-predictive glucose sensor that layers AI atop electrochemical measurements, underscoring incumbent readiness to diversify into broader continuous-monitor portfolios. The FDA then cleared the first 12-month glucose sensor, validating long-wear transcutaneous form factors that reduce patient workload.
Demand Spike for Non-Invasive Neonatal & Critical-Care Monitoring
Wire-free, multi-signal wearables are now prioritized in neonatal ICUs, where adhesive electrodes previously caused skin tears and infection. Flexible epidermal electronics fabricated on ultrathin silicone conformed to infant anatomy and transmitted synchronized pulse oximetry, ECG, and temperature data with negligible motion artifact. Contactless photoplethysmography produced mean heart-rate deviation of –0.2 bpm versus reference methods, supporting adoption for infants in isolette environments. Masimo’s joint project with March of Dimes to supply FDA-cleared home baby monitors demonstrates commercialization beyond hospital walls. Collectively, these efforts re-position neonatal monitoring from episodic spot-checks toward unobtrusive continuous oversight.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Complex & lengthy regulatory approvals | -1.2% | Global; most stringent in EU under MDR | Medium term (2-4 years) |
High device & sensor replacement cost | -0.8% | Emerging markets, cost-sensitive systems | Short term (≤ 2 years) |
Limited clinician training in TC monitoring workflows | -0.6% | Worldwide; pronounced in developing regions | Medium term (2-4 years) |
Skin-tone accuracy bias triggering extra validation | -0.4% | Global; regulatory focus in North America | Short term (≤ 2 years) |
Source: Mordor Intelligence
Complex & Lengthy Regulatory Approvals
Europe’s Medical Device Regulation widened classification scope to include stand-alone software, compelling manufacturers to run full clinical evaluations and post-market surveillance for transcutaneous systems. In the United States, Class II filings must show substantial equivalence with predicate devices and prove accuracy across diverse patient groups, often extending bench-to-bedside timelines. Although recent guidance permits limited data waivers, companies still prepare extensive technical dossiers for MDR and 510(k) submissions, straining smaller entrants and slowing iteration cycles. Divergent U.S.–EU evidence expectations oblige global firms to conduct parallel regulatory strategies, adding up-front compliance costs that can dampen innovation velocity.
High Device & Sensor Replacement Cost
Up-front system prices and frequent sensor swaps weigh on adoption in budget-capped facilities. Health-economic studies show transcutaneous monitoring lowers complications long term, yet capital budgets and per-procedure tariffs rarely capture those downstream savings. U.S. Medicare requires detailed documentation for coverage, imposing administrative overhead that can deter smaller clinics. Emerging healthcare systems face out-of-pocket models that amplify cost sensitivity. To sidestep procurement obstacles, suppliers are piloting bundled-payment agreements that link device fees to outcome metrics, easing cash-flow constraints while aligning incentives.
Segment Analysis
By Application: Blood Gas Dominates, Wound Healing Accelerates
Blood Gas Monitoring accounted for 41.44% of the transcutaneous monitors market size in 2024, reflecting decades of evidence that end-tidal and skin-based measurements reduce invasive sampling frequency in intensive-care suites. Integration with ventilator dashboards further cements its role in respiratory management. Wound Healing, though smaller, is advancing at a 7.12% CAGR. Hyperbaric clinics rely on transcutaneous oxygen (TcPO₂) to triage limb-salvage candidates; values below 30 mmHg flag compromised microcirculation, prompting adjunctive therapy. As funding for diabetic-foot programs rises, TcPO₂ is becoming a routine prognostic marker, placing this niche on a rapid ascent.
The convergence of expanded hyperbaric coverage and portable TcPO₂ devices creates favorable conditions for outpatient wound centers. Societies now list TcPO₂ as a pre-operative measure for peripheral arterial disease, embedding the test in vascular algorithms. Meanwhile, AI-enhanced capnography is spilling into sleep-diagnostic toolkits, foreshadowing new overlaps between pulmonary and wound-care domains. Consequently, the transcutaneous monitors market is widening its clinical footprint without cannibalizing incumbent segments.
Note: Segment shares of all individual segments available upon report purchase
By End User: Hospitals Hold Share, Specialty Clinics Gain Momentum
Hospitals retained 67.78% of revenue in 2024 as critical-care units depend on round-the-clock physiology data. Yet Specialty Clinics are registering 7.19% CAGR because portable monitors now suit outpatient infusion centers and dialysis suites. Ambulatory Surgical Centers deploy single-use sensors to flag hypoventilation episodes during conscious sedation, mitigating post-op complications.
Philips’ decision to move its Healthdot business into smartQare highlights an ecosystem pivot: open platforms that aggregate feeds from multiple vendors are edging out proprietary silos. The model improves staffing efficiency; one Dutch pilot demonstrated 47% less routine vitals collection when continuous wireless sensors fed directly into electronic medical records. Budget-minded clinics view such labor offsets as justification for capital outlay, fuelling demand beyond hospital campuses.
By Parameter Monitored: CO₂ Leads, Combined Parameters Outperform
CO₂ probes captured 44.41% of 2024 sales, reinforcing their superiority in ventilation titration. However, Combined Parameters systems are expanding at 7.03% CAGR as integrated boards collect CO₂, O₂, pulse oximetry, and surface temperature simultaneously. Multisensor packages cut bedside clutter and lower total device count, an important factor as ICU beds host more infusion pumps and infusion lines.
Recent research replaced heated polarographic cells with multiparameter luminescence arrays that last 20,000 hours before recalibration. Cardiac-monitor specialist iRhythm licensed BioIntelliSense silicon to enrich its arrhythmia patches with continuous oximetry and skin-temperature data, signaling cross-pollination between cardiology and respiratory care markets. These alliances forecast an era where the transcutaneous monitors market migrates toward platform economics rather than single-function components.

Note: Segment shares of all individual segments available upon report purchase
By Patient Age Group: Adult Volume, Neonatal Velocity
Adults generated 45.89% of 2024 turnover owing to chronic-disease prevalence and ICU throughput. Neonatal systems, though less than one-quarter of shipments, show a 7.21% annual rise as clinicians prioritize atraumatic designs. Soft epidermal patches trimmed motion artifact by 40% compared to adhesive electrodes, improving alarm accuracy and nursing workflow. Contactless imaging photoplethysmography, already validated against reference monitors, enters trial use in high-acuity nurseries and post-discharge home programs.
Sensor fusion algorithms tailor alarm thresholds to neonatal physiology, minimizing false positives that otherwise desensitize staff. The resulting performance gains accelerate purchasing cycles as hospitals refurbish legacy fleets to meet updated safety standards. For suppliers, the neonatal growth spurt offers a proving ground for technologies later repackaged for broader pediatric and geriatric audiences.
Geography Analysis
North America continues to anchor the transcutaneous monitors market through robust reimbursement, integrated care networks, and a track record of technology uptake. Medicare covers multiple use cases, from ambulatory ECGs to continuous capnography, encouraging hospital procurement even during budget squeezes. BD’s USD 4.2 billion purchase of Edwards Lifesciences’ critical-care unit exemplifies scale-seeking consolidation aimed at building end-to-end monitoring ecosystems. Masimo’s healthcare segment grew 10% in 2024 to USD 1,395 million, reflecting high replacement demand for advanced pulse oximeters and capnometers.
Asia-Pacific is the fastest-growing region at 7.23% CAGR, propelled by aging demographics, infrastructure upgrades, and harmonizing device rules. National reimbursement codes in Japan now bundle continuous oxygen monitoring into postoperative packages, while India’s Ayushman Bharat scheme broadens public funding for critical-care instrumentation. Because many facilities leapfrog older wired technology, suppliers that offer mobile, cloud-linked monitors gain early-mover advantages. The region’s dense innovation hubs also accelerate sensor R&D; several photoacoustic startups in South Korea and Singapore secured Series B funding for wearable capnographs in 2025.
Europe remains a sizeable but increasingly regulated arena. MDR enforcement lengthens submission lead-times, yet it also stabilizes quality expectations, which benefits manufacturers with strong clinical datasets. Roche’s AI-assisted glucose sensor received CE Mark clearance in 2025 under the new rules, proving that evidence-rich dossiers can still move efficiently. Regional procurement patterns favor devices with proven workflow integrations; thus, platforms capable of merging with hospital EMRs see smoother tender wins. While currency volatility and varied national insurance models complicate pricing, the demand for neonatal and wound-healing monitors is rising as speciality clinics across Germany and France adopt hyperbaric programs.

Competitive Landscape
The transcutaneous monitors market is moderately fragmented. Incumbent device makers defend share by embedding analytics software and by forming alliances that extend their hardware into remote settings. Masimo, whose SET pulse oximetry features in all of the top 10 U.S. hospitals ranked by Newsweek in 2024, leverages proven outcome data to secure formulary preference. Philips, GE HealthCare, and Dräger compete through interoperability, pitching vendor-neutral hubs that aggregate telemetry to frontline tablets.
Acquisitions underscore a shift toward portfolio breadth. BD added Edwards’ hemodynamic lines to pair catheter-based pressure readings with skin-level gas metrics, rolling these under a unified smart-connected-care unit. Teleflex’s July 2025 purchase of BIOTRONIK’s vascular intervention business widens its procedural footprint and may create downstream demand for real-time oxygenation feedback during limb revascularization. On the partnership front, open-source data standards are emerging; firms that publish well-documented APIs attract third-party algorithm developers, making their hardware sticky in hospital IT ecosystems.
Smaller innovators, often spun out of university labs, focus on sensor miniaturization and skin-tone-agnostic optics. Many adopt licensing models, feeding OEM pipelines rather than building full marketing channels. While their agile R&D can threaten commoditization, the capital and regulatory muscle of large strategics still dominates high-volume tenders. Overall, the market rewards firms that merge best-in-class hardware with SaaS-style analytics and that demonstrate cost offsets in high-acuity settings.
Transcutaneous Monitors Industry Leaders
-
Sentec AG
-
Radiometer
-
Primed AB
-
Koninklijke Philips N.V.
-
HUMARES GMBH
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- July 2025: Teleflex completed its acquisition of BIOTRONIK’s Vascular Intervention business for EUR 760 million (USD 825 million), adding peripheral intervention devices with expected H2 2025 revenue of EUR 177 million.
- May 2025: Zynex filed a 510(k) for its NiCO Laser Pulse Oximeter, designed to improve accuracy across darker skin tones by combining laser wavelength selection with carbon-monoxide detection.
- April 2025: Epiminder obtained FDA De Novo authorization for Minder, the first implantable continuous EEG monitor for drug-resistant epilepsy, with U.S. launch slated for late 2025.
- February 2025: Medtronic received FDA clearance for BrainSense Adaptive deep-brain-stimulation technology, which adjusts therapy using real-time neural feedback for Parkinson’s disease.
Global Transcutaneous Monitors Market Report Scope
As per scope, transcutaneous monitors are a highly trending tool for monitoring and measuring oxygenation (tcpO2) and ventilation (tcpCO2).
The Transcutaneous Monitors Market is Segmented by Application Type (Wound Healing, Blood Gas Monitoring, Respiratory Care, Sleep Diagnostics), End User (Hospitals, Ambulatory Surgical Centers, Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD million for the above segments.
By Application | Wound Healing | ||
Blood Gas Monitoring | |||
Respiratory Care | |||
Sleep Diagnostics | |||
Others | |||
By End User | Hospitals | ||
Ambulatory Surgical Centers | |||
Specialty Clinics | |||
Others | |||
By Parameter Monitored | Transcutaneous CO2 | ||
Transcutaneous O2 | |||
Bilirubin | |||
Combined Parameters | |||
By Patient Age Group | Neonates | ||
Pediatric | |||
Adult | |||
Geriatric | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Wound Healing |
Blood Gas Monitoring |
Respiratory Care |
Sleep Diagnostics |
Others |
Hospitals |
Ambulatory Surgical Centers |
Specialty Clinics |
Others |
Transcutaneous CO2 |
Transcutaneous O2 |
Bilirubin |
Combined Parameters |
Neonates |
Pediatric |
Adult |
Geriatric |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
Australia | |
South Korea | |
Rest of Asia-Pacific | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the current value of the transcutaneous monitors market?
The market is valued at USD 278.39 million in 2025 and is projected to reach USD 378.74 million by 2030, growing at a 6.35% CAGR.
Which application segment generates the most revenue?
Blood Gas Monitoring leads with 41.44% of 2024 revenue, reflecting its entrenched use in intensive-care ventilation management.
Why are specialty clinics adopting transcutaneous monitors faster than hospitals?
Portable, interoperable devices let clinics monitor patients continuously without intensive capital build-outs, supporting a 7.19% CAGR through 2030.
Which patient group shows the highest growth potential?
Neonates represent the fastest-growing age group at 7.21% CAGR, thanks to soft epidermal sensors that avoid skin trauma and enable continuous vital-sign capture.
How are new regulations affecting product launches in Europe?
The EU Medical Device Regulation demands broader clinical evidence and post-market tracking, lengthening launch timelines but raising quality standards for all entrants.
What technological innovation is most likely to reshape the transcutaneous monitors industry next?
Multi-parameter luminescence sensors that operate without heating elements are expected to drive platform consolidation and extend wear-time, positioning suppliers for new home-care and outpatient applications.
Page last updated on: July 7, 2025